- Verastem Oncology will present preliminary data on expansion cohorts and dose-escalation portion evaluating VS-6766 along with Defactinib in KRAS Mutant Advanced Solid Tumors patients.
- The company will conduct an investor conference call meeting after virtual poster presentation and conduct discussions on the data.
Verastem Oncology, Inc., has reportedly announced that an abstract, showcasing preliminary outcomes from the on-going investigator-initiated clinical trial assessing VS-6766 (RAF/MEK inhibitor), along with defactinib (FAK inhibitor), has been chosen for a virtual poster presentation at virtual AACR (American Association for Cancer Research) 2020 annual meet, which will be held between April 27-28, 2020. The company has been developing this drug to discover a novel therapy for treating patients with KRAS mutant advanced solid tumors.
For the uninitiated, Verastem Oncology, Inc., is an American commercial biopharmaceutical company dedicated to commercializing and developing new medicines for cancer patients.
As per the reports, the on-going clinical trial is an open-label, dose-escalation, and expansion study. The expansion cohorts are presently on-going in KRAS mutant advanced solid tumors patients including LGSOC (low-grade ovarian cancer), NSCLC (non-small cell lung cancer), and CRC (colorectal cancer). After the virtual data presentation, the company will also conduct an investor conference meeting to conduct discussions on the presented data. The exact time and date of this meeting will be announced soon.
Speaking on which, Brian Stuglik, CEO, Verastem Oncology said that the early clinical outcomes led to the company’s decision to in-license VS-6766 drug candidate earlier this year and boost the development of this clinical trial to develop a novel therapy for KRAS mutant cancer patients. The synergy between defactinib and VS-6766 has been encouraging, and the company is looking forward to sharing the data with scientific and medical communities later this month, says Stuglik.
The company is also planning to commence discussions with regulatory bodies in the first half of 2020, to commence a registration-directed trial evaluating the VS-6766/defactinib combination as early as possible.